ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 657

Serial Screening Shows That 28% of Systemic Lupus Erythematosus Adult Patients Carry an Underlying Primary Immunodeficiency

Sandro F. Perazzio1, Reinaldo Salomao2, Neusa P. Silva3, Magda Carneiro-Sampaio4 and Luis Eduardo C. Andrade5, 1Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, 2Infectology, Federal University of Sao Paulo, Sao Paulo, Brazil, 3Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, 4Pediatrics, Instituto da Criança da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil, 5Rheumatology Division, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Immunodeficiency, immunoglobulin (IG) and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic Lupus Erythematosus (SLE) is known to be associated with deficiency of C1q, C4, and C2. There is high frequency of discoid lesions (2.7%) and SLE (0.5%) in Chronic Granulomatous Disease (CGD). Selective IgA Deficiency (SIgAD) has been associated with juvenile (5.2%) and adult (2.6%) SLE. About 25% of patients with Common Variable Immunodeficiency (CVID) develop autoimmune manifestation, including SLE. Although there are reports of individual primary immunodeficiency (PID) in SLE, there is no systematic study estimating the fraction of SLE adult patients presenting any form of PID. This study aimed to estimate the prevalence of overall PID in a cohort of SLE patients and healthy controls, and to compare the clinical characteristics of the SLE patients with and without PID.

Methods: 300 SLE patients (ACR criteria) and 301 controls (blood donors) underwent clinical examination and were evaluated for total hemolytic complement (CH50), C2, C3, C4A and C4B  gene copy number, immunoglobulin isotypes and IgG subclasses, as well as quantification of the oxidative burst in neutrophils. Patients who presented any laboratory indication of PID underwent a novel examination after 60 days for confirmation. Patients with active disease and abnormal results were followed and underwent novel tests after the end of the flare or excluded if no remission was attained up to the end of the study. Cases with low C2 serum levels underwent C2 gene analysis by PCR for confirmation. Those who presented altered unexplained CH50 underwent C1q determination. Those with C4A and/or C4B low copy number had C4 serum levels determined. Diagnosis of PID was established according to “2009 International Union of Immunological Societies Expert Committee on PID”.

Results: There were 84 SLE patients (28%) and 10 controls (3.33%) with established diagnosis of PID (p<0.001). SLE patients had a significantly (p<0.01) higher frequency of IgG2 deficiency (n=37; 12.3%), IgG3 deficiency (n=24; 8%), IgG4 deficiency (n=11; 3.6%), and IgM Deficiency (n=24; 8%) as compared to HC (0.3%, 0%, 0%, and 1.6%, respectively). One female patient presented neutrophil oxidative burst profile compatible with CGD gene carrier status (0.33%). There were no cases of C2, C3, C4 or C1q deficiency, CVID, CGD, Hyper-IgM and Hyper-IgE syndromes. Patients with IgG3 or IgG4deficiency presented higher frequency of lupus nephropathy and those with IgM deficiency presented higher prevalence of oral ulcers. Overall PID was not associated with most SLE clinical manifestations, infection rate, immunosuppressant use, age at disease onset, disease duration, comorbidity, SLEDAI and SLICC-DI.

Conclusion: Over one quarter of SLE patients presented some form of PID, largely represented by immunoglobulin deficiency. Due to the important role of immunoglobulins in the clearance of immunocomplex, apoptotic bodies and pathogens, low levels of these components might induce a state of frequent and persistent immunological stimulation, which may foster autoimmunity development in genetically predisposed individuals. Our results suggest that an underlying immunodeficiency state may be involved in the disease pathophysiology in a substantial fraction of SLE patients.


Disclosure:

S. F. Perazzio,
None;

R. Salomao,
None;

N. P. Silva,

FAPESP,

2;

M. Carneiro-Sampaio,
None;

L. E. C. Andrade,

Fleury Medicine and Health Laboratories,

5.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serial-screening-shows-that-28-of-systemic-lupus-erythematosus-adult-patients-carry-an-underlying-primary-immunodeficiency/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology